Literature DB >> 17380294

Minimally immunogenic decellularized porcine valve provides in situ recellularization as a stentless bioprosthetic valve.

Shigemitsu Iwai1, Kei Torikai, Chris M Coppin, Yoshiki Sawa.   

Abstract

Currently used bioprosthetic valves have several limitations such as calcification and functional deterioration, and revitalization through cellular ingrowth is impossible. To overcome these obstacles, we have developed a minimally immunogenic tissue-engineered valve that consists of an unfixed, decellularized porcine valve scaffold capable of being spontaneously revitalized in vivo after implantation. Porcine aortic root tissue was decellularized using detergents such as sodium lauryl sulfate and Triton X-100. The porcine valve was treated very gently and plenty of time was allowed for constituents to diffuse in and out of the matrix. In a preliminary study, a piece of decellularized porcine valve tissue was implanted into the rat subdermal space for 14 and 60 days and the structural integrity and calcification were evaluated. As an in vivo valve replacement model, the decellularized porcine valve was implanted in the pulmonary valve position in dogs and functional and histological evaluation was performed after 1, 2, and 6 months. Histological examination showed that the newly developed detergent treatment effectively removed cellular debris from the porcine aortic tissue. Decellularized porcine valve tissue implanted subdermally in rats showed minimal inflammatory cell infiltration and calcification. In the valve replacement model, spontaneous reendothelialization and repopulation of the medial cells were observed within 2 months, and good valve function without regurgitation was observed by echocardiography up to 6 months. The minimally immunogenic decellularized porcine valve proved effective in mitigating postimplant calcification and provided a suitable matrix for revitalizing prostheses through in situ recellularization, cellular ingrowth, and tissue remodeling.

Entities:  

Mesh:

Year:  2007        PMID: 17380294     DOI: 10.1007/s10047-006-0360-1

Source DB:  PubMed          Journal:  J Artif Organs        ISSN: 1434-7229            Impact factor:   1.731


  13 in total

1.  Ross operation with a tissue-engineered heart valve.

Authors:  Pascal M Dohmen; Alexander Lembcke; Holger Hotz; Dietmar Kivelitz; Wolfgang F Konertz
Journal:  Ann Thorac Surg       Date:  2002-11       Impact factor: 4.330

2.  Novel tissue-engineered biodegradable material for reconstruction of vascular wall.

Authors:  Shigemitsu Iwai; Yoshiki Sawa; Satoshi Taketani; Kei Torikai; Koichiro Hirakawa; Hikaru Matsuda
Journal:  Ann Thorac Surg       Date:  2005-11       Impact factor: 4.330

3.  Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization.

Authors:  T Asahara; H Masuda; T Takahashi; C Kalka; C Pastore; M Silver; M Kearne; M Magner; J M Isner
Journal:  Circ Res       Date:  1999-08-06       Impact factor: 17.367

4.  Fibronectin-hepatocyte growth factor enhances reendothelialization in tissue-engineered heart valve.

Authors:  Takeyoshi Ota; Yoshiki Sawa; Shigemitsu Iwai; Takashi Kitajima; Yuichiro Ueda; Chris Coppin; Hikaru Matsuda; Yutaka Okita
Journal:  Ann Thorac Surg       Date:  2005-11       Impact factor: 4.330

5.  The SynerGraft valve: a new acellular (nonglutaraldehyde-fixed) tissue heart valve for autologous recellularization first experimental studies before clinical implantation.

Authors:  M F O'Brien; S Goldstein; S Walsh; K S Black; R Elkins; D Clarke
Journal:  Semin Thorac Cardiovasc Surg       Date:  1999-10

6.  Tissue engineering of heart valves: decellularized porcine and human valve scaffolds differ importantly in residual potential to attract monocytic cells.

Authors:  Erwin Rieder; Gernot Seebacher; Marie-Theres Kasimir; Eva Eichmair; Birgitta Winter; Barbara Dekan; Ernst Wolner; Paul Simon; Guenter Weigel
Journal:  Circulation       Date:  2005-05-23       Impact factor: 29.690

7.  Biodegradable polymer with collagen microsponge serves as a new bioengineered cardiovascular prosthesis.

Authors:  Shigemitsu Iwai; Yoshiki Sawa; Hajime Ichikawa; Satoshi Taketani; Eiichiro Uchimura; Guoping Chen; Masayuki Hara; Jun Miyake; Hikaru Matsuda
Journal:  J Thorac Cardiovasc Surg       Date:  2004-09       Impact factor: 5.209

8.  Evidence for circulating bone marrow-derived endothelial cells.

Authors:  Q Shi; S Rafii; M H Wu; E S Wijelath; C Yu; A Ishida; Y Fujita; S Kothari; R Mohle; L R Sauvage; M A Moore; R F Storb; W P Hammond
Journal:  Blood       Date:  1998-07-15       Impact factor: 22.113

9.  Tissue engineering of heart valves--human endothelial cell seeding of detergent acellularized porcine valves.

Authors:  A Bader; T Schilling; O E Teebken; G Brandes; T Herden; G Steinhoff; A Haverich
Journal:  Eur J Cardiothorac Surg       Date:  1998-09       Impact factor: 4.191

10.  Early failure of the tissue engineered porcine heart valve SYNERGRAFT in pediatric patients.

Authors:  P Simon; M T Kasimir; G Seebacher; G Weigel; R Ullrich; U Salzer-Muhar; E Rieder; E Wolner
Journal:  Eur J Cardiothorac Surg       Date:  2003-06       Impact factor: 4.191

View more
  17 in total

1.  Engineering analysis of the effects of bulging sinuses in a newly designed pediatric pulmonary heart valve on hemodynamic function.

Authors:  Ichiro Suzuki; Yasuyuki Shiraishi; Shota Yabe; Yusuke Tsuboko; Telma Keiko Sugai; Ken Matsue; Takeyoshi Kameyama; Yoshifumi Saijo; Takashi Tanaka; Yoshihiro Okamoto; Zhonggang Feng; Takako Miyazaki; Masaaki Yamagishi; Makoto Yoshizawa; Mitsuo Umezu; Tomoyuki Yambe
Journal:  J Artif Organs       Date:  2011-09-29       Impact factor: 1.731

2.  Study on the physical properties of tissue-engineered blood vessels made by chemical cross-linking and polymer-tissue cross-linking.

Authors:  Kwangwoo Nam; Ayako Murakoshi; Tsuyoshi Kimura; Toshiya Fujisato; Soichiro Kitamura; Akio Kishida
Journal:  J Artif Organs       Date:  2009-03-29       Impact factor: 1.731

Review 3.  Journal of Artificial Organs 2007: the year in review.

Authors:  Y Sawa; E Tatsumi; A Funakubo; T Horiuchi; K Iwasaki; A Kishida; T Masuzawa; K Matsuda; M Nishimura; T Nishimura; Y Tomizawa; T Yamaoka; H Watanabe
Journal:  J Artif Organs       Date:  2008-04-15       Impact factor: 1.731

Review 4.  Next-generation tissue-engineered heart valves with repair, remodelling and regeneration capacity.

Authors:  Emanuela S Fioretta; Sarah E Motta; Valentina Lintas; Sandra Loerakker; Kevin K Parker; Frank P T Baaijens; Volkmar Falk; Simon P Hoerstrup; Maximilian Y Emmert
Journal:  Nat Rev Cardiol       Date:  2020-09-09       Impact factor: 32.419

Review 5.  Immunogenicity in xenogeneic scaffold generation: antigen removal vs. decellularization.

Authors:  Maelene L Wong; Leigh G Griffiths
Journal:  Acta Biomater       Date:  2014-01-31       Impact factor: 8.947

6.  CD133 antibody conjugation to decellularized human heart valves intended for circulating cell capture.

Authors:  John D Vossler; Young Min Ju; J Koudy Williams; Steven Goldstein; James Hamlin; Sang Jin Lee; James J Yoo; Anthony Atala
Journal:  Biomed Mater       Date:  2015-09-03       Impact factor: 3.715

7.  A comparison of three methods of decellularization of pig corneas to reduce immunogenicity.

Authors:  Whayoung Lee; Yuko Miyagawa; Cassandra Long; David K C Cooper; Hidetaka Hara
Journal:  Int J Ophthalmol       Date:  2014-08-18       Impact factor: 1.779

8.  Decellularized ureter for tissue-engineered small-caliber vascular graft.

Authors:  Yuji Narita; Hideaki Kagami; Hiroshi Matsunuma; Yosuke Murase; Minoru Ueda; Yuichi Ueda
Journal:  J Artif Organs       Date:  2008-07-06       Impact factor: 1.731

Review 9.  Antigen removal for the production of biomechanically functional, xenogeneic tissue grafts.

Authors:  Derek D Cissell; Jerry C Hu; Leigh G Griffiths; Kyriacos A Athanasiou
Journal:  J Biomech       Date:  2013-11-08       Impact factor: 2.712

Review 10.  Recellularization of decellularized heart valves: Progress toward the tissue-engineered heart valve.

Authors:  Mitchell C VeDepo; Michael S Detamore; Richard A Hopkins; Gabriel L Converse
Journal:  J Tissue Eng       Date:  2017-08-25       Impact factor: 7.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.